The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment.
The effects of dopamine D1 and D2 receptor agonists and antagonists were studied in eight Cebus apella monkeys previously treated with haloperidol for two years. SKF 81297 (specific D1 receptor agonist) induced oral hyperkinesia of variable intensity (P less than 0.01): some of the monkeys developed extreme lip smacking, tonque protrusions and licking movements while others developed only slight lip movements. A combined treatment of SKF 81297 with LY 171555 (full D2 receptor agonist) or SCH 23390 (D1 receptor antagonist) inhibited the oral hyperkinesia induced by SKF 81297 (P less than 0.01, P less than 0.02, respectively). Raclopride (D2 receptor antagonist) did not statistically change oral hyperkinesia (P less than 0.2), although five monkeys showed increased oral movements; most of these monkeys had pre-existing hyperkinesia. Treatment with SCH 23390 or raclopride resulted in an identical dystonic/cataleptic syndrome. SKF 81297 inhibited the dystonia induced by SCH 23390, while it did not significantly affect raclopride dystonia. The investigation indicates that oral dyskinesia may be related to an imbalance in D1 receptor and D2 receptor stimulation in favor of D1 receptors. The question now is whether D1 receptor antagonists, which may have antipsychotic potential, will produce tardive dyskinesia after long-term use.
Peacock
L
L
Sct. Hans Hospital, Roskilde, Denmark.
Lublin
H
H
Gerlach
J
J
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001552:Benzazepines / Q000494:pharmacology; D001767:Blinking / Q000187:drug effects; D002428:Cebus; D015259:Dopamine Agents / Q000494:pharmacology*; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology; D004421:Dystonia / Q000139:chemically induced / Q000503:physiopathology; D004873:Ergolines / Q000494:pharmacology; D005260:Female; D006120:Grooming / Q000187:drug effects; D006993:Hypnotics and Sedatives; D008297:Male; D019257:Quinpirole; D020891:Raclopride; D011954:Receptors, Dopamine / Q000187:drug effects*; D012457:Salicylamides / Q000494:pharmacology; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*
D014150:Antipsychotic Agents; D001552:Benzazepines; D015259:Dopamine Agents; D004873:Ergolines; D006993:Hypnotics and Sedatives; D011954:Receptors, Dopamine; D012457:Salicylamides; D019257:Quinpirole; D020891:Raclopride; C067113:SK&F 81297